Information on the target
Ottobock SE & Co. KGaA, a publicly traded global MedTech company, has entered into an agreement to sell its Human Mobility business segment to the international medical technology firm DHCare on June 19, 2026. The transaction is expected to close in the second half of 2026. This strategic divestiture aligns with Ottobock's ongoing focus on its core business areas, particularly in prosthetics and neuro-orthotics, where the company sees the greatest potential for development.
Oliver Jakobi, CEO of Ottobock SE & Co. KGaA, emphasized the importance of this sale in sharpening the company's strategic focus. He stated, "With the sale of our wheelchair business, we are honing our strategic focus on our core business. At the same time, we gain DHCare as the right investor for Human Mobility, which has built a technologically advanced business with high clinical credibility and strong customer relationships. We are confident that Human Mobility will have excellent growth opportunities in the new environment."
Industry overview in the target’s specific country
The Medical Prosthetics industry in Germany is characterized by a robust framework of innovation and technological advancement. Germany is recognized as a leader in the development and manufacturing of medical devices, including prosthetics, driven by a strong emphasis on research and development. The country boasts a well-established healthcare system that supports the integration of advanced medical technologies, ensuring that patients have access to high-quality prosthetic solutions.
In recent years, the demand for prosthetic devices has surged, fueled by an aging population and increasing incidences of chronic diseases and disabilities. The German market is particularly notable for its focus on personalized prosthetic solutions, which are tailored to meet the specific needs of individual patients. This trend is supported by advancements in materials science and digital technologies, enabling the creation of lighter, more durable, and functionally superior prosthetics.
Furthermore, Germany's regulatory environment is conducive to innovation, with stringent quality standards that ensure the safety and efficacy of medical devices. The collaboration between industry players, research institutions, and healthcare providers fosters a dynamic ecosystem that accelerates the development of next-generation prosthetic technologies. As a result, the German Medical Prosthetics industry is poised for continued growth, driven by technological advancements and an increasing focus on patient-centered care.
The rationale behind the deal The decision to divest the Human Mobility segment is a strategic move by Ottobock to concentrate its resources and efforts on its core competencies in prosthetics and neuro-orthotics. By selling this non-core business, Ottobock aims …